Ash Stevens Receives 2014 Lilly Global Supplier Award - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ash Stevens Receives 2014 Lilly Global Supplier Award


Ash Stevens, a provider of global contract pharmaceutical drug substance development and API manufacturing services, received a 2014 Lilly Global Supplier Award.

“We are honored to receive this award and recognition from Eli Lilly and Company. Ash Stevens has a rich history that exceeds 50 years conducting innovative chemical research to develop and manufacture a wide variety of active pharmaceutical ingredients," said Dr. Stephen Munk, president and CEO.

To date, Ash Stevens has received twelve FDA manufacturing approvals for new APIs, including four fast-track manufacturing approvals for the active ingredients in the oncology drugs Velcade, Vidaza, Clolar, and Iclusig.

Source: Ash Stevens

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here